Eli Lilly and Company (NYSE:LLY) declared that a panel of the U.S. FDA held a “constructive discussion” on the benefit-risk profile of its investigational cancer drug necitumumab. The senior VP, product development and medical affairs for Lilly Oncology, Richard Gaynor stated that they  are encouraged by the Committee’s constructive discussion […]